Chemoradiotherapy Optimized for Immunotherapy for Limited Stage Small Cell Lung Cancer (COILSS)
For decades, standard treatment for limited-stage small cell lung cancer (LS-SCLC) has been concurrent chemotherapy and thoracic radiotherapy. It recently became standard to treat patients with immunotherapy after chemoradiotherapy. Optimizing chemoradiotherapy delivery for the safe and effective delivery of immunotherapy is now critical. We will perform a prospective trial with twenty-five patients testing a chemoradiotherapy strategy designed to minimize the risk of serious adverse events that may interfere with successful treatment. Our program includes chemotherapeutic agents that are relatively unlikely to cause immunosuppression, a shortened and risk-adapted radiotherapy course that reduces irradiation of the lungs, esophagus and heart, and an enhanced toxicity monitoring strategy informed by wearable device data. Positive findings will lead to larger multi-institutional trials to establish our new treatment approach for the treatment of LS-SCLC with chemoradiotherapy and immunotherapy, with the overall goals of preserving quality-of-life and improving rates of disease cure.
